<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130156</url>
  </required_header>
  <id_info>
    <org_study_id>DTR-886-401</org_study_id>
    <nct_id>NCT00130156</nct_id>
  </id_info>
  <brief_title>Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of Bunazosin with
      Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential
      hypertension accompanied by metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study will comprise a 1 to 2-week washout period, a 5-week mono therapy period
      with AngiotensinⅡantagonist, and an 8-week alpha blocker add-on treatment period. Total study
      period will be 15 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Week 0, Week 4, Week 9, Week 13.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability.</measure>
    <time_frame>Week 4, Week 9, Week 13.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bunazosin</intervention_name>
    <description>Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Detantol-R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Doxaben XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartin</intervention_name>
    <description>After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects with mild to moderate essential hypertension, with the following criteria:

          1. Washout period (Week -2)

               -  Male or female subjects aged 20 to 80 years

               -  Systolic blood pressure (SBP):140 mm Hg but &lt;180 mm Hg and/or diastolic blood
                  pressure (DBP):90 mm Hg but &lt;110 mm Hg

               -  Subjects who have given written informed consent prior to participation in the
                  trial and who undertake to comply with the protocol

          2. Angiotensin II antagonist mono-therapy period (week 0)

               -  Subjects with systolic blood pressure &gt;= 140 mm Hg but &lt;180 mm Hg and/or
                  diastolic blood pressure &gt;= 90 mm Hg but &lt;110 mm Hg

               -  Presence of any 2 of the following 4 risk factors

               -  Waist circumference: male &gt; 90 cm, female &gt; 80 cm

               -  Triglycerides &gt;= 150 mg/dl

               -  HDL cholesterol: male &lt; 40 mg/dl, female &lt; 50 mg/dl

               -  Fasting glucose &gt;= 110 mg/dl

          3. Angiotensin II antagonist with add-on Bunazosin or Doxazosin treatment period (Week 5)

               -  SBP &gt;=140 mm Hg or decrease &lt; 10 % OR

               -  DBP &gt;=90 mm Hg or decrease &lt; 10 % comparing the blood pressure at the entry of
                  the Angiotensin II antagonist mono-therapy period.

        Exclusion Criteria:

        Subjects with the following conditions are not eligible for participation：

        a) Washout period (Week -1 or -2)

          -  Subjects with severe hypertension (SBP&gt;=180 mm Hg or DBP&gt;=110 mm Hg).

          -  Subjects who have proven or suspected hypersensitivity to quinazoline derivatives

          -  Subjects who have a history of alcohol or drug abuse.

          -  Subjects with past or present evidence of cancer

          -  Subjects who have a past history of arterial fibrillation, heart failure (LVEF&lt;40%),
             acute coronary syndrome, myocardial infarction, stroke or severe arrhythmia.

          -  Subjects who are severely obese (BMI&gt;30 kg/m2)

          -  Women who are pregnant or lactating or suspected of being pregnant.

          -  Subjects who have previously participated in any clinical trial of new or unapproved
             substances within the 12 weeks before starting of washout period

          -  Subjects on other anti-hypertensive or lipid-lowering medication

          -  Inability to return for scheduled visits or comply with any other aspect of the
             Protocol

          -  Subjects with poorly controlled diabetes mellitus (HbA1c &gt; 10%)

          -  Subjects with concurrent serious hepatic or renal disorders (defined as AST and/or ALT
             &gt; 3 times upper normal limit or Cr &gt; 2mg/dl).

          -  Subjects who, in the opinion of the investigators, are poor medical candidates or pose
             any other risk for therapy with an investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ya-hui Cheng</last_name>
    <role>Study Director</role>
    <affiliation>Medical Affairs Department , Eisai Taiwan Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital.</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>SBP</keyword>
  <keyword>DBP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Bunazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

